Should we treat patients with chronic hepatitis C on the waiting list?

Journal of Hepatology

Volumn 42, Issue 4, 2005, Pages 456-462

  Everson, Gregory T ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN;

ANEMIA; CLINICAL TRIAL; FOLLOW UP; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; NEUTROPENIA; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 14844321568     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.01.012     Document Type: Review

References (42)

1. World Health Organization Weekly epidemiological record 74 1999 421 428
2. G.L. Armstrong, M.J. Alter, G.M. McQuillan, and H.S. Margolis The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States Hepatology 31 2000 777 782
3. E. Kenny-Walsh Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group N Engl J Med 340 1999 1228 1233
4. M. Wiese, F. Berr, M. Lafrenz, H. Porst, and U. Oesen Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study Hepatology 32 2000 91 96
5. L.B. Seeff, Z. Buskell-Bales, E.C. Wright, S.J. Durako, H.J. Alter, F.L. Iber, and F.B. Hollinger Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group N Engl J Med 327 1992 1906 1911
6. L.B. Seeff Natural history of hepatitis C Am J Med 107 1999 10S 15S
7. A.J. Rodger, S. Roberts, A. Lanigan, S. Bowden, T. Brown, and N. Crofts Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975 Hepatology 32 2000 582 587
8. M.J. Tong, N.S. el-Farra, A.R. Reikes, and R.L. Co Clinical outcomes after transfusion-associated hepatitis C N Engl J Med 332 1995 1463 1466
9. G. Fattovich, G. Giustina, F. Degos, F. Tremolada, G. Diodati, and P. Almasio Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463 472
10. L. Serfaty, H. Aumaitre, O. Chazouilleres, A.M. Bonnand, O. Rosmorduc, and R.E. Poupon Determinants of outcome of compensated hepatitis C virus-related cirrhosis Hepatology 27 1998 1435 1440
11. K.Q. Hu, and M.J. Tong The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States Hepatology 29 1999 1311 1316
12. M.H. Khan, G.C. Farrell, K. Byth, R. Lin, M. Weltman, and J. George Which patients with hepatitis C develop liver complications? Hepatology 31 2000 513 520
13. R.H. Wiesner, M. Sorrell, and F. Villamil International liver transplantation society expert panel. Report of the first international liver transplantation society expert panel Consensus conference on liver transplantation and Hepatitis C Liver Transpl 39 2003 S1 S9
14. D.B. Strader, T. Wright, D.L. Thomas, and L.B. Seeff AASLD practice guideline: diagnosis, management, and treatment of Hepatitis C Hepatology 39 2004 1147 1171
15. G.L. Davis, L.A. Balart, E.R. Schiff, K. Lindsay, H.C. Bodenheimer, and R.P. Perrillo Treatment of chronic hepatitis C, with recombinant Interferon alfa. A multicenter randomized, controlled trial. Hepatitis interventional therapy group N Engl J Med. 321 1989 1501 1506
16. A.M. Di Bisceglie, P. Martin, C. Kassianides, M. Lisker-Melman, L. Murray, and J. Waggoner Recombinant Interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial N Engl J Med 321 1989 1506 1510
17. J.H. Hoofnagle, and A.M. Di Bisceglie The treatment of chronic viral hepatitis N Engl J Med 336 1997 347 356
18. J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, and V.K. Rustgi Interferon alfa-2b alone or in combination with Ribavirin as initial rreatment for chronic hepatitis C. Hepatitis interventional therapy group N Engl J Med 339 1998 1485 1492
19. G.L. Davis, R. Esteban-Mur, V. Rustgi, J. Hoefs, S.C. Gordon, and C. Trepo Interferon alfa-2b alone or in combination with Ribavirin for the treatment of relapse of chronic hepatitis C. International hepatitis interventional therapy group N Engl J Med 339 1998 1493 1499
20. E.J. Heathcote, M.L. Shiffman, W.G. Cooksley, G.M. Dusheiko, S.S. Lee, and L. Balart Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis N Engl J Med 343 2000 1673 1680
21. M.W. Fried, M.L. Shiffman, R.K. Reddy, C. Smith, G. Marino, and F. Goncales Peginterferon alfa-2a plus ribavirin for chronic hepatitis C Infection New Engl J Med 347 2002 975 982
22. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M.L. Shiffman, and R. Reindollar Peginterferon alfa-2b plus Ribavirin compared to Interferon alfa-2b plus Ribavirin for initial treatment of chronic hepatitis C: A randomized trial. International Hepatitis Interventional Therapy Group Lancet 358 2001 958 965
23. S.J. Hadziyannis, H. Sette, T.R. Morgan, V. Balan, M. Diago, and P. Marcellin Pegasys International Study Group. Peginterferon alfa-2a and Ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and Ribavirin dose Ann Intern Med 140 2004 346 355
24. M.L. Shiffman, A.M. Di Bisceglie, K.L. Lindsay, C. Morishima, E.C. Wright, and G.T. Everson Peginterferon alfa-2a and Ribavirin in patients with chronic hepatitis C who have failed prior treatment. HALT-C Trial Group Gastroenterology 126 2004 1015 1023
25. G.T. Everson, J.C. Hoefs, and P. Malet Impaired virologic response in patients with advanced liver disease due to chronic hepatitis C is independently linked to severity of disease: results from the HALT C trial Hepatology 40 2004 180A
26. G.T. Everson, J.F. Trotter, and M. Kugelmas Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol [low-accelerating-dose-regimen] Hepatology 36 2002 297A
27. G.T. Everson Treatment of patients with hepatitis C virus on the waiting list Liver Transpl 9 2003 S90 S94
28. X. Forns, M. Garcia-Retortillo, T. Serrano, A. Feliu, F. Suarez, and M. de la Mata Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation J Hepatol 39 2003 389 396
29. R.M. Thomas, J.J. Brems, G. Guzman-Hartman, S. Yong, P. Cavaliere, and D.H. Van Thiel Infection with chronic hepatitis C virus and liver transplantation: A role for Interferon therapy before transplantation Liver Transpl 9 2003 905 915
30. J.S. Crippin, T. McCashland, N. Terrault, P. Sheiner, and M.R. Charlton A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation Liver Transpl 8 2002 350 355
31. E.J. Heathcote Treatment considerations in patients with hepatitis C and cirrhosis J Clin Gastroenterol 37 2003 395 398
32. R.J. Fontana, G.T. Everson, S. Tuteja, H.E. Vargas, and M.L. Shiffman Controversies in the management of hepatitis C patiens with advanced fibrosis and cirrhosis Clin Gastroenterol Hepatol 2 2004 183 197
33. D.T. Dietrich, R. Wasserman, N. Brau, T.I. Hassanein, E.J. Bini, P.J. Bowers, and M.S. Sulkowski Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa Am J Gastroenterol 98 2003 2491 2499
34. A. Makiyama, Y. Itoh, A. Kasahara, Y. Imai, S. Kawata, and K. Yoshioka Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy Cancer 101 2004 1616 1622
35. M.L. Shiffman, C.M. Hofmann, E.B. Thompson, A. Ferreira-Gonzalez, M.J. Contos, and A. Koshy Relationship between biochemical, virological and histological response during interferon treatment of chronic hepatitis C Hepatology 26 1997 780 785
36. T. Poynard, J. McHutchison, M. Manns, C. Trepo, K. Lindsay, and Z. Goodman Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313
37. H. Yoshida, Y. Shiratori, M. Moriyama, Y. Arakawa, T. Ide, and M. Sata Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan: IHIT study group-inhibition of hepatocarcinogenesis by interferon therapy Ann Intern Med 131 1999 174 181
38. M.L. Shiffman, C.M. Hofmann, M.J. Contos, V.A. Luketic, A.J. Sanyal, and R.K. Sterling A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia Gastroenterology 117 1999 1164 1172
39. L. Alric, M. Duffaut, J. Selves, K. Sandre, M. Mularczyck, and J. Izopet Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial J Hepatol 35 2001 272 278
40. W.M. Lee, J.L. Dienstag, K.L. Lindsay, A.S. Lok, H.L. Bonkovsky, and M.L. Shiffman The HALT C trial group Controlled Clinical Trials 25 2004 472 492
41. N. Afdhal, R. Levine, and M. Black Colchicine versus PEG-Intron longterm: 1 year data from the COPILOT study (abstr) Gastroenterology 122 2002 218
42. N. Afdhal, B. Freilich, R. Levine, M. Black, R. Brown, and H. Monsour Colchicine versus Peg-Intron long-term (COPILOT) trial: interim analysis of clinical outcomes at Year 2 Hepatology 40 2004 238A